Literature DB >> 10441556

Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles.

M Höhne1, S Thaler, J C Dudda, B Groner, B S Schnierle.   

Abstract

The incorporation of human immunodeficiency virus-type-2 (HIV-2) envelope glycoprotein into murine leukemia virus (MuLV) particles was studied in a transient transfection packaging cell system. We observed that wild-type HIV-2 envelope protein or a frameshift mutant with 187 unrelated carboxyl-terminal residues did not allow the formation of infectious retroviral particles. In view of recent findings that an HIV-1 envelope protein variant with a shortened cytoplasmic domain was incorporated into MuLV particles, we constructed carboxyl-terminal truncations of the HIV-2 envelope protein. An envelope variant with 18 cytoplasmic amino acids formed only very few viral pseudotypes. The further removal of an additional 11 amino acids allowed the efficient pseudotyping of MuLV particles. As with the HIV-1 envelope protein, an HIV-2 envelope variant with 7 cytoplasmic amino acids was incorporated into functional MuLV particles. The pseudotyped vectors obtained are able to infect human CD4/CXCR4-expressing cells. Cell lines expressing human CD4 and other coreceptors could not be infected. This retroviral vector will prove useful for the study of HIV infection events mediated by the HIV-2 envelope glycoproteins, as well as for the targeting of CD4+ cells in the context of gene therapy of AIDS. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441556     DOI: 10.1006/viro.1999.9847

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.

Authors:  Jean K Millet; Tiffany Tang; Lakshmi Nathan; Javier A Jaimes; Hung-Lun Hsu; Susan Daniel; Gary R Whittaker
Journal:  J Vis Exp       Date:  2019-03-01       Impact factor: 1.355

2.  Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism.

Authors:  L Bruett; J E Clements
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.

Authors:  Paolo Abada; Beth Noble; Paula M Cannon
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors.

Authors:  I Christodoulopoulos; P M Cannon
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 5.  The role of matrix in HIV-1 envelope glycoprotein incorporation.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Trends Microbiol       Date:  2014-06-02       Impact factor: 17.079

6.  The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors.

Authors:  Dimitri Lavillette; Mariana Marin; Alessia Ruggieri; François Mallet; François-Loïc Cosset; David Kabat
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.

Authors:  Tsanan Giroglou; Jindrich Cinatl; Holger Rabenau; Christian Drosten; Harald Schwalbe; Hans Wilhelm Doerr; Dorothee von Laer
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.

Authors:  Dimple Khetawat; Christopher C Broder
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

9.  Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors.

Authors:  Sandra Siegert; Sonja Thaler; Ralf Wagner; Barbara S Schnierle
Journal:  AIDS Res Ther       Date:  2005-09-12       Impact factor: 2.250

10.  Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction.

Authors:  S R Witting; P Vallanda; A L Gamble
Journal:  Gene Ther       Date:  2013-05-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.